Congress trades

Baxter International Inc. (BAX)

Medical Instruments & Supplies, listed on NYSE.

S&P 500360 insider transactions127 Congress tradeslast filed Sep 3, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

EarningsQ3 FY2026 · reported Oct 29, 2026

Baxter International beat by 2.3% on revenue.

Revenue $2.98B against a $2.91B consensus. EPS was $0.58 a share under GAAP; the $0.52 consensus is for adjusted EPS.

Revenue

Reported$2.98B
Consensus$2.91B

Beat 4Miss 2

EPS against the consensus, quarter by quarter. Outlined: a GAAP figure against an adjusted consensus.

Next report Feb 11, 2027. Consensus $0.60 a share.

Every quarter

Money managers13F filings for Jun 30, 2026

690

institutions reported Baxter International shares in 13F filings for Jun 30, 2026. BlackRock, Inc. held the largest stake, $1.7B.

The largest holders

BlackRock, Inc.$1.7B
Pzena Investment Management LLC$1.4B
Dodge & Cox$1.2B
Every holder

CongressSTOCK Act disclosures to the House and Senate

20 Congress disclosures shown, from 3 members.

24dMedian delayof the 45 day limit
11 buys · 9 sellsPurchases and sales in the disclosures shown

3 members of Congress report a position in BAX, by our estimate. Who holds it

Every Congress trade in BAXEvery disclosure
Companyfrom the company's filings and listing, as of Nov 10, 2026

About Baxter International Inc.

Exchange
NYSE
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Chief executive
Andrew Hider
Employees
37,500
Listed since
Oct 27, 1981
Market value
$13.6B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$1.40
Dividend yield
0.15%

www.baxter.com

Earnings6 reported quarters · next on Feb 11, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Oct 29, 2026$0.58$0.52$3.0B$2.9BEPS beat, GAAPRevenue beat
Q2 FY2026reported Jul 30, 2026$0.56$0.37$3.0B$2.8BEPS beatRevenue beat
Q1 FY2026reported Apr 30, 2026$0.36$0.31$2.7B$2.6BEPS beatRevenue beat
Q4 FY2025reported Feb 12, 2026$0.44$0.53$3.0B$2.8BEPS missRevenue beat
Q3 FY2025reported Oct 30, 2025$0.69$0.60$2.8B$2.8BEPS beatRevenue in line
Q2 FY2025reported Jul 31, 2025$0.59$0.60$2.8B$2.9BEPS missRevenue miss

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on BAX yet. Briefs from every company we cover.

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on BAX, newest first
FirmRatingTargetActionDate
JefferiesNot stated$25Target set
BarclaysUnderweight$20Initiated
StifelHold$28Raised from $24
UBSNeutral$25Raised from $19
Goldman SachsNeutral$21Target set
Evercore ISIOutperform$24Target set
Deutsche BankNot stated$20Target set
Morgan StanleyUnderweight$15Target set

Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.

4 other firms rated BAX in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 12, 2026.

Proxy statementas filed for fiscal 2025 · proxy filed Mar 23, 2026

Executive pay

Reazur Rasul’s pay came to $5.2M for fiscal 2025.
ExecutiveSalaryStock awardsOtherTotal
Reazur RasulExecutive Vice President and Group President, Healthcare Systems & Technologies$800K$3.0M$1.5M$5.2M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 3 executives who have since left the company are named in that filing and not shown here. Read the filing

13F filings13F positions as of Jun 30, 2026

Institutional holders

HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$1.7B81,842,105+3.1%15.83%
Pzena Investment Management LLC$1.4B65,295,393+1.2%12.63%
Dodge & Cox$1.2B58,386,345+2.0%11.29%
FMR LLC$1.1B53,913,831+16.5%10.43%
Vanguard Capital Management LLC$719.6M33,754,280+0.7%6.53%
Vanguard Portfolio Management LLC$512.9M24,057,190+0.3%4.65%
State Street Corp$439.4M20,600,468+3.1%4.00%
Greenhaven Associates Inc$304.6M14,285,228-0.2%2.76%
Geode Capital Management, LLC$300.6M14,123,689+2.6%2.73%
Invesco Ltd.$263.6M12,361,881-5.8%2.39%
UBS Group AG$203.2M9,529,309+120.6%1.84%
First Pacific Advisors, LP$162.4M7,618,145+13.7%1.47%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Other Form 4 activity (20)
InsiderEventSharesDate
Julie FosterPresident, Front Line CareTax withholding2,098Sep 2, 2026
Andrew P. HiderPresident and CEOTax withholding54,276Sep 2, 2026
James TeaffPresident, CCSTax withholding750Sep 1, 2026
William A. Ampofo IIDirectorStock award12,836May 5, 2026
Jeffrey A. CraigDirectorStock award12,836May 5, 2026
Michael R. McDonnellDirectorStock award12,836May 5, 2026
David Brent ShaferDirectorStock award12,836May 5, 2026
Patricia MorrisonDirectorStock award12,836May 5, 2026
Nancy M. SchlichtingDirectorStock award12,836May 5, 2026
Amy McBride WendellDirectorStock award12,836May 5, 2026
David S. WilkesDirectorStock award12,836May 5, 2026
James TeaffPresident, CCSOther Form 4 entry (see filing)55,119Apr 1, 2026
Steven P. WallacePresident, Adv. SurgeryOther Form 4 entry (see filing)67,972Apr 1, 2026
Julie FosterPresident, Front Line CareOther Form 4 entry (see filing)25,862Apr 1, 2026
Joel T. GradeEVP and CFOTax withholding8,153Mar 6, 2026
Reazur RasulEVP, Group Pres, HealthcareTax withholding12,674Mar 6, 2026
David S. RosenbloomEVP and General CounselTax withholding6,620Mar 6, 2026
Maria Cecilia SorianoGroup Pres., ITT & Pharma.Tax withholding2,848Mar 6, 2026
Anita A. ZielinskiSVP, CAO and ControllerTax withholding1,932Mar 6, 2026
Anita A. ZielinskiSVP, CAO and ControllerStock award30,864Feb 27, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

STOCK Act20 disclosures of 127 on record · median 24d of the 45 allowed

Congress trades in BAX

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Ro KhannaStockPurchase$1,001 - $15,000+53.1% since the tradeEstimated entry price $17.21, close on Fri May 1Current price $26.34, close on Wed Nov 11May 1, 2026Jun 9, 202639d
Ro KhannaStockPurchase$1,001 - $15,000+52.3% since the tradeEstimated entry price $17.30, close on Fri May 15Current price $26.34, close on Wed Nov 11May 15, 2026Jun 9, 202625d
Ro KhannaStockPurchase$1,001 - $15,000+36.3% since the tradeEstimated entry price $19.33, close on Wed May 27Current price $26.34, close on Wed Nov 11May 27, 2026Jun 9, 202613d
Ro KhannaStockSale$1,001 - $15,000+45.0% since the saleEstimated exit price $18.16, close on Fri Apr 24Current price $26.34, close on Wed Nov 11Apr 24, 2026May 11, 202617d
Ro KhannaStockSale$1,001 - $15,000+49.4% since the saleEstimated exit price $17.63, close on Mon Apr 13Current price $26.34, close on Wed Nov 11Apr 13, 2026May 11, 202628d
Ro KhannaStockSale$1,001 - $15,000+66.7% since the saleEstimated exit price $15.80, close on Mon Mar 30Current price $26.34, close on Wed Nov 11Mar 30, 2026Apr 7, 20268d
Michael T. McCaulStockPurchase$100,001 - $250,000+27.0% since the tradeEstimated entry price $20.74, close on Tue Feb 17Current price $26.34, close on Wed Nov 11Feb 17, 2026Mar 10, 202621d
Ro KhannaStockPurchase$1,001 - $15,000+27.0% since the tradeEstimated entry price $20.74, close on Tue Feb 17Current price $26.34, close on Wed Nov 11Feb 17, 2026Mar 9, 202620d
Michael T. McCaulStockPurchase$50,001 - $100,000+34.0% since the tradeEstimated entry price $19.65, close on Tue Jan 13Current price $26.34, close on Wed Nov 11Jan 13, 2026Feb 11, 202629d
Ro KhannaStockPurchase$1,001 - $15,000+33.5% since the tradeEstimated entry price $19.73, close on Thu Jan 29Current price $26.34, close on Wed Nov 11Jan 29, 2026Feb 6, 20268d
Ro KhannaStockSale$1,001 - $15,000+48.4% since the saleEstimated exit price $17.75, close on Mon Nov 10, 2025Current price $26.34, close on Wed Nov 11Nov 10, 2025Dec 8, 202528d
Lisa C. McClainSpouseStockPurchase$1,001 - $15,000+37.5% since the tradeEstimated entry price $19.16, close on Thu Oct 30, 2025Current price $26.34, close on Wed Nov 11Oct 30, 2025Nov 21, 202522d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+37.5% since the saleEstimated exit price $19.16, close on Thu Oct 30, 2025Current price $26.34, close on Wed Nov 11Oct 30, 2025Nov 21, 202522d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+42.6% since the saleEstimated exit price $18.47, close on Fri Oct 31, 2025Current price $26.34, close on Wed Nov 11Oct 31, 2025Nov 21, 202521d
Lisa C. McClainSpouseStockPurchase$1,001 - $15,000+21.3% since the tradeEstimated entry price $21.71, close on Thu Sep 25, 2025Current price $26.34, close on Wed Nov 11Sep 25, 2025Oct 22, 202527d
Ro KhannaStockSale$1,001 - $15,000+11.9% since the saleEstimated exit price $23.54, close on Wed Sep 3, 2025Current price $26.34, close on Wed Nov 11Sep 3, 2025Oct 3, 202530d
Ro KhannaStockSale$1,001 - $15,000+7.9% since the saleEstimated exit price $24.42, close on Fri Sep 5, 2025Current price $26.34, close on Wed Nov 11Sep 5, 2025Oct 3, 202528d
Ro KhannaStockPurchase$1,001 - $15,000+17.7% since the tradeEstimated entry price $22.38, close on Mon Sep 29, 2025Current price $26.34, close on Wed Nov 11Sep 29, 2025Oct 3, 20254d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+17.4% since the saleEstimated exit price $22.44, close on Mon Aug 4, 2025Current price $26.34, close on Wed Nov 11Aug 4, 2025Sep 12, 202539d
Ro KhannaStockPurchase$1,001 - $15,000+17.4% since the tradeEstimated entry price $22.44, close on Mon Aug 4, 2025Current price $26.34, close on Wed Nov 11Aug 4, 2025Sep 9, 202536d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

Every Congress trade in BAX filterable by party, chamber, type and account.

STOCK Act3 members · estimate, as of Nov 10, 2026

Members of Congress reporting a position

3 members report a position (estimated).
MemberParty, chamberEstimated positionShare of their portfolio
Lucy McBathDemocrat · House$1,001 - $15,0000.2%
Robert BresnahanRepublican · House$1,001 - $15,0000.1%
Debbie Wasserman SchultzDemocrat · House$1,001 - $15,00025.1%

The largest estimated position is in the $1,001 - $15,000 band. Estimate, as of Nov 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 12, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on BAX show and how current they are.

Which members of Congress have traded BAX?

Ro Khanna, Michael T. McCaul and Lisa C. McClain disclosed BAX transactions in the filings shown here.

Which members of Congress hold BAX?

3 members of Congress report a position in BAX in the estimate we hold as of Nov 10, 2026. The estimated positions belong to Lucy McBath, Robert Bresnahan and Debbie Wasserman Schultz. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

Is BAX in the S&P 500 or the Nasdaq 100?

Baxter International Inc. is a current member of the S&P 500, per the membership list we hold as of Nov 12, 2026. Current members of either index get a page here whatever their filing history.

How quickly are BAX trades disclosed?

Congressional disclosures took a median of 24 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track